Find and Pitch Jounalists, Get Your Story Covered

Tags: leadership pharma Research & Development research-development biotech

	Profile	Recent Articles on Subject
1	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: A reporter’s JPM notebook: a look ahead for biopharma VC investing - 5 days ago STAT+: Biotech FogPharma raises $145 million in anticipation of more clinical trials, pharma partnerships - 11 months ago
2	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Musk’s rare disease torpedo, hospitals’ pharma fix and other policies leaders are tracking - 5 days ago PharmaVoice’s Crystal Ball: The industry’s AI future - 15 days ago 3 closely watched drugs that failed in the clinic - about 1 month ago The big rebrand: Why these 4 biopharmas changed their name this year - about 2 months ago Pharma takes aim at a wily foe — the Epstein-Barr virus - 3 months ago 2024 PharmaVoice 100s: Rare Disease Warriors - 3 months ago 2024 PharmaVoice 100s: Trailblazers - 3 months ago California is a life sciences leader. Joe Panetta has been one of its most vocal advocates. - 4 months ago Who’s winning in biotech’s tight market? - 4 months ago Pharma’s ‘it’ therapy — a new drug class gaining steam - 5 months ago Up-and-comers look for an edge in the bustling ADC field - 7 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 8 months ago Where competition is heating up in pharma - 8 months ago The biggest questions hanging over pharma in 2024 - 12 months ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - about 1 year ago Does BioMarin’s CEO shuffle signal bigger changes ahead? - about 1 year ago PharmaVoice 100s: Entrepreneurs - about 1 year ago
3	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Biopharma in 2025: Outlook for Obesity Meds, Drug Prices, Regulation & More - 14 days ago 3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders - 4 months ago
4	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	East Asians under-represented in biopharma leadership - 14 days ago BioMarin’s big day today - 5 months ago
5	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Merck is a new year outlier with its diabetes drug - 19 days ago Biopharma leaders lay out vision for the future of blood cancer treatment - about 1 month ago Is pharma still fearful of the Inflation Reduction Act? - 5 months ago The biotech news you missed this week - 7 months ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 8 months ago Novartis is building a new radioligand plant in China - about 1 year ago
6	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	Biopharma leaders lay out vision for the future of blood cancer treatment - about 1 month ago A biotech’s binary bet ends badly - 7 months ago
7	Angus Chen STAT News Undignified, unfunny journalist. Health, cancer coverage at STAT News. journalismhealthcancer researchSTAT News	Biopharma leaders lay out vision for the future of blood cancer treatment - about 1 month ago
8	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	Biopharma leaders lay out vision for the future of blood cancer treatment - about 1 month ago STAT+: Pharmalittle: End of biotech’s stock market malaise may be near; cancer drug shortages hit rural clinics hard - over 1 year ago
9	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Milk-based therapies could be coming. This biotech CEO is aiming to lead the way. - about 2 months ago Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope. - 5 months ago In a Duchenne market beset by problems, Capricor data marks a bright spot - 6 months ago Behind the powerful computations, AI’s role in pharma is still beset by challenges - 7 months ago 4 offbeat biotechs making a splash in the life sciences - 9 months ago These biotech hotspots are ripe for IPOs - 10 months ago
10	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - 2 months ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 10 months ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - 10 months ago STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more - 10 months ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - 10 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - about 1 year ago STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news - about 1 year ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - about 1 year ago STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market - about 1 year ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - about 1 year ago STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail - over 1 year ago

Journalists covering biopharma